On July 8, 2025, Ladenburg Thalmann, through analyst Kevin DeGeeter, initiated coverage on ORIC Pharmaceuticals (ORIC, Financial) with a "Buy" rating. This initial assessment includes a price target announcement of USD 15.00.
ORIC Pharmaceuticals (ORIC, Financial), known for its innovative approach in the pharmaceutical industry, is now on the radar of notable analysts with this new coverage. The "Buy" rating indicates a positive outlook on ORIC's potential market performance.
This new coverage and price target set the stage for increased interest and closer monitoring of ORIC Pharmaceuticals (ORIC, Financial) by investors and industry followers alike.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for ORIC Pharmaceuticals Inc (ORIC, Financial) is $18.78 with a high estimate of $25.00 and a low estimate of $12.00. The average target implies an upside of 78.92% from the current price of $10.50. More detailed estimate data can be found on the ORIC Pharmaceuticals Inc (ORIC) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, ORIC Pharmaceuticals Inc's (ORIC, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
